Haas DM, Marsh DJ, Dang DT, Parker CB, Wing DA, Simhan HN, et al. Prescription and other medication use in pregnancy. Obstet Gynecol. 2018;131(5):789–98.

Article  PubMed  PubMed Central  Google Scholar 

Ayad M, Costantine MM. Epidemiology of medications use in pregnancy. Semin Perinatol. 2015;39(7):508–11.

Article  PubMed  PubMed Central  Google Scholar 

Van Calsteren K, Gersak K, Sundseth H, Klingmann I, Dewulf L, Van Assche A, et al. Position statement from the European Board and College of Obstetrics & Gynaecology (EBCOG): the use of medicines during pregnancy: call for action. Eur J Obstet Gynecol Reprod Biol. 2016;201:211–4.

Article  PubMed  Google Scholar 

Dude C, Jamieson DJ. Assessment of the safety of common medications used during pregnancy. JAMA. 2021;326(23):2421.

Article  PubMed  Google Scholar 

Sewell CA, Sheehan SM, Gill MS, Henry LM, Bucci-Rechtweg C, Gyamfi-Bannerman C, et al. Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials. Am J Obstet Gynecol. 2022;227(6):805–11.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. Framework for FDA’s real world evidence 2018 [cited 2024 March 6]; https://www.fda.gov/drugs/webinar-framework-fdas-real-world-evidence-program-mar-15-2019.

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Postapproval pregnancy safety studies guidance for industry. 2019.

Wood ME, Andrade SE, Toh S. Safe Expectations: current state and future directions for medication safety in pregnancy research. Clin Ther. 2019;41(12):2467–76.

Article  PubMed  PubMed Central  Google Scholar 

Huybrechts KF, Bateman BT, Hernandez-Diaz S. Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiol Drug Saf. 2019;28(7):906–22.

Article  PubMed  PubMed Central  Google Scholar 

Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome—methodological considerations. Reprod Toxicol. 2008;26(1):36–41.

Article  CAS  PubMed  Google Scholar 

Charlton RA, McGrogan A. Drug safety in pregnancy: data, methods, and challenges. Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy; 2022. p. 1–11.

Badhiwala JH, Karmur BS, Wilson JR. Propensity score matching: a powerful tool for analyzing observational nonrandomized data. Clin Spine Surg. 2021;34(1):22–4.

Article  PubMed  Google Scholar 

Shi X, Wellman R, Heagerty PJ, Nelson JC, Cook AJ. Safety surveillance and the estimation of risk in select populations: flexible methods to control for confounding while targeting marginal comparisons via standardization. Stat Med. 2020;39(4):369–86.

Article  PubMed  Google Scholar 

Suarez EA, Landi SN, Conover MM, Jonsson FM. Bias from restricting to live births when estimating effects of prescription drug use on pregnancy complications: a simulation. Pharmacoepidemiol Drug Saf. 2018;27(3):307–14.

Article  CAS  PubMed  Google Scholar 

Neophytou AM, Kioumourtzoglou MA, Goin DE, Darwin KC, Casey JA. Educational note: addressing special cases of bias that frequently occur in perinatal epidemiology. Int J Epidemiol. 2021;50(1):337–45.

Article  PubMed  Google Scholar 

Gao SY, Wu QJ, Sun C, Zhang TN, Shen ZQ, Liu CX, et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med. 2018;16(1):205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The Reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10): e1001885.

Article  PubMed  PubMed Central  Google Scholar 

Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–94.

Article  PubMed  Google Scholar 

Shamliyan T, Kane RL, Dickinson S. A systematic review of tools used to assess the quality of observational studies that examine incidence or prevalence and risk factors for diseases. J Clin Epidemiol. 2010;63(10):1061–70.

Article  PubMed  Google Scholar 

U.S. National Library of Medicine. Abridged Index Medicus (AIM or ‘‘core clinical’’) journal titles. [cited 2024 March 6]; https://www.nlm.nih.gov/bsd/aim.html.

Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). Br Med J. 2018;14(363): k3532.

Article  Google Scholar 

Sakran R, Shechtman S, Arnon J, Diav-Citrin O. Pregnancy outcome following in-utero exposure to ondansetron: a prospective comparative observational study. Reprod Toxicol. 2021;99:9–14.

Article  CAS  PubMed  Google Scholar 

Zhu Y, Bateman BT, Gray KJ, Hernandez-Diaz S, Mogun H, Straub L, et al. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. Br Med J. 2020;20(369): m1494.

Article  Google Scholar 

Andersson NW, Poulsen HE, Andersen JT. Desloratadine use during pregnancy and risk of adverse fetal outcomes: a nationwide cohort study. J Allergy Clin Immunol Pract. 2020;8(5):1598–605.

Article  PubMed  Google Scholar 

Bateman BT, Hernandez-Diaz S, Straub L, Zhu Y, Gray KJ, Desai RJ, et al. Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. BMJ. 2021;10(372): n102.

Article  Google Scholar 

Pauliat E, Onken M, Weber-Schoendorfer C, Rousson V, Addor MC, Baud D, et al. Pregnancy outcome following first-trimester exposure to fingolimod: a collaborative ENTIS study. Mult Scler. 2021;27(3):475–8.

Article  CAS  PubMed  Google Scholar 

Philipps W, Fietz AK, Meixner K, Bluhmki T, Meister R, Schaefer C, et al. Pregnancy outcome after first-trimester exposure to fosfomycin for the treatment of urinary tract infection: an observational cohort study. Infection. 2020;48(1):57–64.

Article  CAS  PubMed  Google Scholar 

Shapira M, Avrahami I, Mazaki-Tovi S, Shai D, Zemet R, Barzilay E. The safety of early pregnancy exposure to granisetron. Eur J Obstet Gynecol Reprod Biol. 2020;245:35–8.

Article  CAS  PubMed  Google Scholar 

Hakkarainen KM, Juuti R, Burkill S, Geissbuhler Y, Sabido M, Popescu C, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020;13:1756286420951072.

Article  PubMed  PubMed Central  Google Scholar 

Hashimoto Y, Michihata N, Yamana H, Shigemi D, Morita K, Matsui H, et al. Intraocular pressure-lowering medications during pregnancy and risk of neonatal adverse outcomes: a propensity score analysis using a large database. Br J Ophthalmol. 2021;105(10):1390–4.

Article  PubMed  Google Scholar 

Schmidt AB, Lund M, Corn G, Oyen N, Wohlfahrt J, Melbye M. Oral corticosteroids during pregnancy and offspring risk of congenital heart defects: a nationwide cohort study. Int J Epidemiol. 2020;49(2):638–47.

Article  PubMed  Google Scholar 

Yovich JL, Mariappen U, Hinchliffe PM, Dhaliwal SS, Keane KN. MPA given orally during the first trimester for threatened miscarriage carries no specific risk for foetal abnormalities albeit the rate is higher than non-threatened pregnancies. Reprod Biol. 2020;20(3):424–32.

Article  PubMed  Google Scholar 

Namazy JA, Blais L, Andrews EB, Scheuerle AE, Cabana MD, Thorp JM, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020;145(2):528–36 e1.

Pedersen L, Petronis KR, Norgaard M, Mo J, Froslev T, Stephansson O, et al. Risk of adverse birth outcomes after maternal varenicline use: a population-based observational study in Denmark and Sweden. Pharmacoepidemiol Drug Saf. 2020;29(1):94–102.

Article  CAS  PubMed  Google Scholar 

Anderson KN, Ailes EC, Lind JN, Broussard CS, Bitsko RH, Friedman JM, et al. Atypical antipsychotic use during pregnancy and birth defect risk: national birth defects prevention study, 1997–2011. Schizophr Res. 2020;215:81–8.

Article  PubMed  Google Scholar 

Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, et al. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: a population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLoS Med. 2020;17(9): e1003322.

Article